Figure 2.

The protocol of T-cell receptor (TCR) αβ T-cell and B-cell depletion recently developed in haplo-HSC transplantation. The protocol for haplo-HSCT allows infusion of donor HSC, together with high number of γδ T lymphocytes and NK cells. This novel strategy permits, during the early posttransplant period (6–8 weeks), a better control of leukemia cells escaping the preparative regimen, thus preventing disease relapses. In this transplantation setting, in addition to γδ T-cells and NK cells developing late from donor HSC, these promptly available effectors transferred with the graft may immediately exert their graft-versus-leukemia effect and contribute to the control of infections.